Wall Street Zen downgrades Castle Biosciences stock to Hold. Insider sold 8,580 shares

Published on 10/28/2026 at 06:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Wall Street Zen cut Castle Biosciences to Hold on October 24, 2026. Castle Biosciences stock has third-quarter results due November 5, 2026, after market close.

Revenue and dates

Derek Maetzold sold 8,580 shares on October 19, 2026.
Second-quarter revenue reached USD 103.55 million versus USD 86.23 million expected on July 30, 2026.
Castle Biosciences stock was last at USD 34.51 on Nasdaq on October 27, 2026 at 4:00 p.m. ET.

CSTL, US14843C1053, Illustration mit AI erstellt.

Castle Biosciences (ISIN US14843C1053) was downgraded from Buy to Hold by Wall Street Zen on October 24, 2026, while insider Derek Maetzold sold 8,580 shares on October 19, 2026, according to MarketBeat. The next quarterly update is scheduled for November 5, 2026.

Analyst downgrade meets insider sale

The paired developments give investors two competing signals before the next report. Wall Street Zen changed its rating from Buy to Hold, while the October 19 transaction involved 8,580 shares sold at an average USD 31.91, according to MarketBeat. The sale followed a pre-arranged Rule 10b5-1 plan.

What does guidance mean for margins?

Castle raised its full-year 2026 revenue guidance to USD 365 million to USD 375 million from USD 345 million to USD 355 million after its second-quarter performance. The company also projected positive adjusted EBITDA for the third quarter, fourth quarter and full year 2026, according to its Castle Biosciences. In the second quarter, adjusted gross margin was 76.3 percent and adjusted EBITDA was USD 12.4 million.

Three dates shape the story

On June 24, 2026, Roth Capital initiated coverage with a USD 40.00 price target, and on July 30, 2026, Castle reported second-quarter revenue of USD 99.86 million against USD 86.23 million expected, according to MarketBeat. On October 19, 2026, Maetzold sold 8,580 shares under a Rule 10b5-1 plan, according to MarketBeat.

Next reporting date is November 5

Castle Biosciences will release third-quarter and nine-month results for the period ended September 30, 2026, after the market close on November 5, 2026. Management plans a webcast at 4:30 p.m. ET that day, according to the company's press release dated October 15, 2026.

The next test is quarterly execution

Castle Biosciences stock was last at USD 34.51 on Nasdaq on October 27, 2026 at 4:00 p.m. ET. The company enters the report with USD 266.8 million in cash, cash equivalents and marketable investment securities as of June 30, 2026, giving the revenue range and profitability target a clear role in the next market reaction.